Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_151_библиотеки_им_акад_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
10 Мб
Скачать
☆
144 I. Mladenova
https://t.me/med1917
Kuipers 2016). In a population-based cohort study, an increasing incidence of gastric cancer was observed in younger individuals in some countries, highlighting the need for more preventive strategies in younger populations. Future research should explore the reasons for these epidemiologic trends (Wong et al. 2021 ).
9 Conclusions
The risk of developing gastric cancer is dependent on molecular interactions among components including H. pylori virulence factors, the host genotype, environmental factors, etc. Тhey determine the outcome of H. pylori infection.
We could recommend more active detection and treatment of infected children, which should result in specific and effective eradication of H. pylori, reduce the likelihood of transmission of infection, and, as a rule, lead to a reduction in the incidence of gastric cancer in adults.
References
Amieva MR, El-Omar EM (2008) Host-bacterial interactions in Helicobacter pylori infection.
Gastroenterology 134:306–323 Amieva M, Peek RM Jr (2016) Pathobiology of Helicobacter pylori-induced gastric cancer.
Gastroenterol 150:64–78 Ansari S, Yamaoka Y (2019) Helicobacter pylori virulence factors exploiting gastric colonization
and its pathogenicity. Toxins 11:677 Atherton JC, Peek RM Jr, Tham KT, Cover TL, Blaser MJ (1997) Clinical and pathological
importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori.
Gastroenterology 112:92–99 Bakhti SZ, Latifi-Navid S, Safaralizadeh R (2020) Helicobacter pylori-related risk predictors of
gastric cancer: the latest models, challenges, and future prospects. Cancer Med 9:4808–4822 Basso D, Zambon CF, Letley DP et al (2008) Clinical relevance of Helicobacter pylori cagA and
vacA gene polymorphisms. Gastroenterology 135:91–99 Bonvicini F, Baldini L, Pretolani S, Figura N, Epifanio G, Armuzzi A, Miglio F, Gasbarrini G
(1997) Anti-CagA antibodies are associated with atrophic gastritis in a population at high gastric
cancer risk: a morphometric study by computerized image analysis. Ital J Gastroenterol Hepatol
29:409–414 Bornschein J, Selgrad M, Warnecke M et al (2010) H. pylori infection is a key risk factor for
proximal gastric cancer. Dig Dis Sci 55:3124–3131 Bosman FT, Carneiro F, Hruban RH, Theise ND (2010) WHO classification of tumours of the
digestive system. WHO, Geneva, pp 417 Brenner H, Arndt V, Stegmaier C et al (2004) Is Helicobacter pylori infection a necessary condition
for noncardia gastric cancer? Am J Epidemiol 159:252–258 Chan JKC et al (1990) Relationship between high grade and low grade b-cell mucosa-associated
lymphoid tissue lymphoma of the stomach. Am J Pathol 16:115–164 Chen XY, Liu WZ, Shi Y et al (2002) Helicobacter pylori associated gastric diseases and lymphoid
tissue hyperplasia in gastric antral mucosa. J Clin Pathol 55:133–137 Ching CK, Wong BC, Kwok E, Ong L, Covacci A, Lam SK (1996) Prevalence of CagA-bearing
Helicobacter pylori strains detected by the anti-CagA assay in patients with peptic ulcer disease
and in controls. Am J Gastroenterol 91:949–953 Choi YJ, Kim N (2016) Gastric cancer and family history. Korean J Int Med 31:1042–1053
Gastric Cancer and Helicobacter pylori 145
https://t.me/med1917
Cooke CL, Torres J, Solnick JV (2013) Biomarkers of Helicobacter pylori-associated gastric
cancer. Gut Microbes 4:532–540 Correa P (2013) Gastric cancer: overview. Gastroenterol Clin N Am 42:211–217 Cover TL, Blanke SR (2005) Helicobacter pylori VacA, a paradigm for toxin multifunctionality.
Nat Rev Microbiol 3:320–332 Cover TL, Glupczynski Y, Lage AP, Burette A, Tummuru MK, Perez-Perez GI, Blaser MJ (1995)
Serologic detection of infection with cagA+ Helicobacter pylori strains. J Clin Microbiol 33:
1496–1500 den Hoed CM, Kuipers EJ (2016) Gastric cancer: how can we reduce the incidence of this disease?
Curr Gastroenterol Rep 18:34. https://doi.org/10.1007/s11894-016-0506-0 Denic M, Toua ti E, De Reuse H (2020) Review: pathogenesis of Helicobacter pylori infection.
Helicobacter 25(Suppl 1):e12736 Eidt S, Stolte M, Fischer R (1994) Helicobacter pylori gastritis and primary gastric non-Hodgkin’s
lymphomas. J Clin Pathol 47:436–439 Ekstrom AM, Held M, Hansson LE et al (2001) Helicobacter pylori in gastric cancer stablished by
CagA immunoblot as a marker of past infection. Gastroenterology 121:784–791 Engstrand L, Graham DY (2020) Microbiome and gastric cancer. Dig Dis Sci 65:865–873 Enroth H, Engstrand L (1995) Immunomagnetic separation and PCR for detection of Helicobacter
pylori in water and stool specimens. J Clin Microbiol 33:2162–2165 Everett SM, Axon AT (1997) Early gastric cancer in Europe. Gut 41:142–150 Ferguson DA Jr, Li C, Patel NR, Mayberry WR, Chi DS, Thomas E (1993) Isolation of
Helicobacter pylori from saliva. J Clin Microbiol 31:2802–2804 Ferguson DA Jr, Jiang C, Chi DS, Laffan JJ, Li C, Thomas E (1999) Evaluation of two string tests
for obtaining gastric juice for culture, nested-PCR detection, and combined single- and double-
stranded conformational polymorphism discrimination of Helicobacter pylori. Dig Dis Sci 44:
2056–2062 Fischbach W, Dragosics B, Kolve-Goebeler M-E et al (2000) Primary gastric B-cell lymphoma:
results of a prospective multicenter study. Gastroenterology 119:1191–1202 Forman D (1995) The prevalence of H. pylori infection in gastric cancer. Aliment Pharmacol Ther
9(suppl. 2):71–76 Gaddy JA, Radin JN, Loh JT, Zhang F, Washington MK, Peek RM Jr, Algood HM, Cover TL
(2013) High dietary salt intake exacerbates Helicobacter pylori-induced gastric carcinogenesis.
Infect Immun 81:2258–2267 Gong EJ, Choi KD (2019) Diagnosis and treatment of gastric mucosa-associated lymphoid tissue
lymphoma. Korean J Gastroenterol 74:304–313 Gunathilake M, Lee J-H, Choi I-J, Kim Y-I, Kim J-S (2021) Effect of the interaction between
dietary patterns and the gastric microbiome on the risk of gastric cancer. Nutrients 13:2692 Gunn MC, Stephens JC, Stewart JA, Rathbone BJ, West KP (1998) The significance of cagA and
vacA subtypes of Helicobacter pylori in the pathogenesis of inflammation and peptic ulceration.
J Clin Pathol 51:761–764 Hamilton R, Aatonen LA (2000) Tumors of digestive system. IARC, Lyon, pp 39–52 Hatakeyama M (2014) Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run
carcinogenesis. Cell Host Microbe 15:306–316 Hattori T (1986) Development of adenocarcinomas in the stomach. Cancer 57:1528–1534 Hill MG (1991) Bacterial N-nitrosation and gastric carcinogenesis in humans. Ital J Gastroenterol
23:17–23 Hopkins RJ, Vial PA, Ferreccio C, Ovalle J, Prado P, Sotomayor V, Russell RG, Wasserman SS,
Morris JG Jr (1993) Seroprevalence of Helicobacter pylori in Chile: vegetables may serve as one
route of transmission. J Infect Dis 168:222–226 Hou L, El-Omar EM, Chen J et al (2007) Polymorphisms in Th1-type cell-mediated response genes
and risk of gastric cancer. Carcinogenesis 28:118–123
146 I. Mladenova
https://t.me/med1917
Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A (2012) Gastric cancer:
classification, histology and application of molecular pathology. J Gastrointest Oncol 3:
251–261 Huang Q, Shi J, Feng A et al (2011) Gastric cardiac carcinomas involving the esophagus are more
adequately staged as gastric cancers by the 7th edition of the American Joint Commission on
Cancer Staging System. Mod Pathol 24:138–146 Isaacson P, Wright FDH (1984) Extranodal malignant lymphoma arising from mucosa associated
lymphoid tissue. Cancer 53:2512–2524 Ito M, Haruma K, Kamada T et al (2002) Helicobacter pylori eradication therapy improves atrophic
gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis.
Aliment Pharmacol Ther 16:1449–1456 Ito M, Tanaka S, Chayama K (2021) Characteristics and early diagnosis of gastric cancer discov-
ered after Helicobacter pylori eradication. Gut Liver 15:338–345 Jang S, Jones KR, Olsen CH et al (2010) Epidemiological link between gastric disease and
polymorphisms in VacA and CagA. J Clin Microbiol 48:559–567 Jeyamani L, Jayarajan J, Leelakrishnan V, Swaminathan M (2018) CagA and VacA genes of
Helicobacter pylori and their clinical relevance. Indian J Pathol Microbiol 61:66–69 Kabir S (2004) Detection of Helicobacter pylori DNA in feces and saliva by polymerase chain
reaction: a review. Helicobacter 9:115–123 Kaźmierczak-Siedlecka K, Ruszkowski J, Skonieczna-Żydecka K, Jędrzejczak J, Folwarski M,
Makarewicz W (2020) Gastrointestinal cancers: the role of microbiota in carcinogenesis and the
role of probiotics and microbiota in anti-cancer therapy efficacy. Cent Eur J Immunol 45:476–
487 Kuipers EJ (1999) Helicobacter pylori, MALT lymphoma and gastric cancer. J Chemother
11(Suppl 2):25 Kuipers EJ, Uyterlinde AM, Peña AS, Roosendaal R, Pals G, Nelis GF, Festen HP, Meuwissen SG
(1995a) Long-term sequelae of Helicobacter pylori gastritis. Lancet 345(8964):1525–1528 Kuipers EJ, Perez-Perez GI, Meuwissen SG, Blaser MJ (1995b) Helicobacter pylori and atrophic
gastritis: importance of the cagA status. J Natl Cancer Inst 87:1777–1780 Kumar S, Patel GK, Ghoshal UC (2021) Helicobacter pylori-induced inflammation: possible factors
modulating the risk of gastric cancer. Pathogens 10:1099 Laurén P (1965) The two histological main types of gastric carcinoma: diffuse and so-called
intestinal-type carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol
Scand 64:31–49 Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, Graham DY (2016) Association
between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and
meta-analysis. Gastroenterol 150:1113–1124 Leung WK, Siu KL, Kwok CK, Chan SY, Sung R, Sung JJ (1999) Isolation of Helicobacter pylori
from vomitus in children and its implication in gastro-oral transmission. Am J Gastroenterol 94:
2881–2884 Li L, Yu C (2019) Helicobacter pylori infection following endoscopic resection of early gastric
cancer. Biomed Res Int 16:9824964 Lin Y, Kawai S, Sasakabe T, Nagata C, Naito M, Tanaka K, Sugawara Y, Mizoue T, Sawada N,
Matsuo K et al (2021) Effects of Helicobacter pylori eradication on gastric cancer incidence in
the Japanese population: a systematic evidence review. Jpn J Clin Oncol 51:1158–1170 Malfertheiner P, Bornschein J, Selgrad M (2010) Role of Helicobacter pylori infection in gastric
cancer pathogenesis: a chance for prevention. J Dig Dis 11:2–11 Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F,
Gasbarrini A, Atherton J, Graham DY et al (2017) Management of Helicobacter pylori
infection—the Maastricht V/Florence consensus report. Gut 66:6–30 Matsuhisa T, Matsukura N, Yamada N (2004) Topography of chronic active gastritis in
Helicobacter pylori-positive Asian populations: age-, gender-and endoscopic diagnosis-
matched study. J Gastroenterol 39:324–
328
Gastric Cancer and Helicobacter pylori 147
https://t.me/med1917
Matysiak-Budnik T, Jamet P, Ruskoné-Fourmestraux A, de Mascarel A, Velten M, Maynadié M,
Woronoff AS, Trétarre B, Marrer E, Delafosse P, Ligier K, Lapôtre Ledoux B, Daubisse L,
Bouzid L, Orazio S, Cowppli-Bony A, Monnereau A (2019) Gastric MALT lymphoma in a
population-based study in France: clinical features, treatments and survival. Aliment Pharmacol
Ther 50:654–663 McColl KE, el-Omar E, Gillen D (1998) Interactions between H. pylori infection, gastric acid
secretion and anti-secretory therapy. Br Med Bull 54:121–138 Mera R, Fontham ET, Bravo LE et al (2005) Long term follow up of patients treated for
Helicobacter pylori infection. Gut 54:1536–1540 Mladenova I (2021) Clinical relevance of Helicobacter pylori infection. J Clin Med 10:3473 Mladenova-Hristova I, Grekova O, Patel A (2017) Zoonotic potential of helicobacter spp.
J Microbiol Immunol and Infect 50:265–269 Montalbán C et al (1995a) Gastric B-cell MALT lymphoma. Clinicopathological study and
evaluation of the prognostic factors in 1443 patients. Ann Oncol 6:355–362 Montalbán C, Manzanal A, Castrillo JM, Escribano L, Bellas C (1995b) Low grade gastric B-cell
MALT lymphoma progressing into high grade lymphoma. Clonal identity of the two stages of
the tumour, unusual bone involvement and leukemic dissemination. Histopathology 27:89–91 Murakami T (1971) Patholomorphological diagnosis. Definition and gross classification of early
gastric cancer. Gann Monohr Cancer Res 11:53–55 Na H-K, Lee JY (2017) Molecular basis of alcohol-related gastric and colon cancer. Int J Mol Sci
18:1116 Osato MS, Le HH et al (1997) Houseflies are an unlikely reservoir for H. pylori. Workshop on
gastroduodenal pathology and H. pylori, Lisboa 1997, Abstracts 03/146 Pandey R, Misra V, Misra SP, Dwivedi M, Kumar A, Tiwari BK (2010) Helicobacter pylori and
gastric cancer. Asian Pac J Cancer Prev 11:583–588 Parsonnet F, Orentreich V (1997) Risk for gastric cancer in people with CagA positive or CagA
negative Helicobacterpylori infection. Gut 40:297–301 Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK
(1991) Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 325:1127–
1131 Parsonnet J et al (1992) Symptoms and risk factor of Helicobacter pylori infection in a cohort of
epidemiologists. Gastroenterology 102:41–46 Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelman JH,
Friedman GD (1994) Helicobacter pylori infection and gastric lymphoma. N Engl J Med 330:
1267–1271 Parsonnet J, Shmuely H, Haggerty T (1999) Fecal and oral shedding of Helicobacter pylori from
healthy infected adults. JAMA 282:2240–2245 Perez-Perez GI, Rothenbacher D, Brenner H (2004) Epidemiology of Helicobacter pylori infection.
Helicobacter 9:1S–6S Plummer M, Franceschi S, Vignat J, Forman D, de Martel C (2015) Global burden of gastric cancer
attributable to Helicobacter pylori. Int J Cancer 136:487–490 Portal-Celhay C, Perez-Perez GI (2006) Immune responses to Helicobacter pylori colonization:
mechanisms and clinical outcomes. Clin Sci (Lond) 110:305–314 Queralt N, Bartolome R, Araujo R (2005) Detection of Helicobacter pylori DNA in human faeces
and water with different levels of faecal pollution in the north-east of Spain. J Appl Microbiol
98:889–895 Raymond J, Thiberg JM, Chevalier C, Kalach N, Bergeret M, Labigne A, Dauga C (2004) Genetic
and transmission analysis of Helicobacter pylori strains within a family. Emerg Infect Dis 10:
1816–1821 Resende C, Gomes CP, Machado JC (2020) Review: gastric cancer: basic aspects. Helicobacter 25
(Suppl 1):e12739 Ribaldone DG, Simondi D, Petrini E, Astegiano M, Durazzo M (2019) Non-invasive biomarkers
for gastric cancer diagnosis: ready for prime time? Minerva Biotecnol 31:3–10
148 I. Mladenova
https://t.me/med1917
Ruskone-Fourmestraux A, Fischbach W, Aleman BM et al (2011) EGILS consensus report. Gastric
extranodal marginal zone B-cell lymphoma of MALT. Gut 60:747–758 Sahay P, Axon A (1996) Reservoirs of H. pylori and modes of transmission. Helicobacter
1:175–182 Siewert JR, Stein HJ (1998) Classification of adenocarcinoma of the oesophagogastric junction.
Br J Surg 85:1457–1459 Sipponen P, Kekki M, Haapakoski J, Ihamaki T, Siurala M (1985) Gastric cancer risk in chronic
atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 35:173–177 Stathis A, Chini C, Bertoni F et al (2009) Long-term outcome following Helicobacter pylori
eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell
lymphoma of MALT type. Ann Oncol 20:1086–1093 Sukri A, Hanafiah A, Zin NM, Kosai NR (2020) Epidemiology and role of Helicobacter pylori
virulence factors in gastric cancer carcinogenesis. APMIS 128:150–161 Take S, Mizuno M, Ishiki K et al (2005) The effect of eradicating Helicobacter pylori on the
development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 100:
1037–1042 Taneike I, Tamura Y, Shimizu T, Yamashiro Y, Yamamoto T (2001) Helicobacter pylori
intrafamilial infections: change in source of infection of a child from father to mother after
eradication therapy. Clin Diagn Lab Immunol 8:731–739 Thiel A, Ristimäki A (2012) Gastric cancer: basic aspects. Helicobacter 17(Suppl 1):26–29 Thomas JE, Gibson GR, Darboe MK et al (1992) Isolation of Helicobacter pylori from human
faeces. Lancet 340:1194–1195 Tsujii M, Kawano S, at al. (1995) Mechanism of ammonia-induced gastric carcinogenesis in rats.
Carcinogenesis 16:563–566 Uno Y (2019) Prevention of gastric cancer by Helicobacter pylori eradication: a review from Japan.
Cancer Med 8:3992–4000 Venerito M, Vasapolli R, Rokkas T, Malfertheiner P (2018) Gastric cancer: epidemiology, preven-
tion, and therapy. Helicobacter 23:e12518 Venerito M, Ford AC, Rokkas T, Malfertheiner P (2020) Review: prevention and management of
gastric cancer. Helicobacter 25(Suppl. 1):e12740 Wada A, Yamasaki E, Hirayama T (2004) Helicobacter pylori vacuolating cytotoxin, VacA, is
responsible for gastric ulceration. J Biochem 136:741–746 Warren JR, Marshall B (1983) Unidentified curved bacilli on gastric epithelium in active chronic
gastritis. Lancet 1:1273–1275 Watari J, Chen N, Amenta PS, Fukui H, Oshima T, Tomita T, Miwa H, Lim KJ, Das KM (2014)
Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and
pathogenesis of gastric cancer development. World J Gastroenterol 20:5461–5473 Webb PM, Knight T, Greaves S et al (1994) Relation between infection with Helicobacter pylori
and living conditions in childhood: evidence for person to person transmission in early life.
Br Med J 308:750–753 Wei J, Nagy TA, Vilgelm A, Zaika E, Ogden SR, Romero-Gallo J, Piazuelo MB, Correa P,
Washington MK, El-Rifai W, Peek RM, Zaika A (2010) Regulation of p53 tumor suppressor
by Helicobacter pylori in gastric epithelial cells. Gastroenterology 139:1333– 1343 Wen J, Lau HC-H, Peppelenbosch M, Yu J (2021) Gastric microbiota beyond H. pylori: an
emerging critical character in gastric carcinogenesis. Biomedicine 9:1680 Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung
SY, Fong DY, Ho J, Ching CK, Chen JS, China Gastric Cancer Study Group (2004)
Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a
randomized controlled trial. JAMA 291:187–194 Wong MCS, Huang J, Chan PSF, Choi P, Lao XQ, Chan SM, Teoh A, Liang P (2021) Global
incidence and mortality of gastric cancer, 1980–2018. JAMA Netw Open 4(7):e2118457 Wotherspoon AC (1996) Gastric MALT lymphoma and Helicobacter pylori. Yale J Biol Med 69:
61–68
Gastric Cancer and Helicobacter pylori 149
https://t.me/med1917
Wotherspoon AC, Doglioni C, Diss TC et al (1993) Regression of primary low-grade B-cell gastric
lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori.
Lancet 342:575–577 Wu JY, Lee YC, Graham DY (2019) Eradication of Helicobacter pylori to prevent gastric cancer: a
critical appraisal. Expert Rev Gastroenterol Hepatol 13:17–24 Yamaoka Y, Kato M, Asaka M (2008) Geographic differences in gastric cancer incidence can be
explained by differences between Helicobacter pylori strains. Intern Med 47:1077–1083 Yang Y, Ji R, Zhao X, Cao X, Wang Q, Jiang Q, Zhang Y, Zheng W, Wu X, Yang A (2021)
Alterations in gastric mucosal microbiota in gastric carcinogenesis: a systematic review and
meta-analysis. Front Med 8:754959 Ychou M, Boige V, Pignon JP et al (2011) Perioperative chemotherapy compared with surgery
alone for resectable gastroesophageal adenocarcinoma: an NCLCC and FFCD multicenter
phase III trial. J Clin Oncol 29:1715–1721 You WC, Brown LM, Zhang L et al (2006) Randomized double-blind factorial trial of three
treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 98:
974–983
Role of Neuromodulators in Regulation
https://t.me/med1917
of the Tumor Microenvironment of Gastric and Colorectal Cancers
Debanjan Chakroborty and Chandrani Sarkar
Abstract
Gastrointestinal cancers represent one of the greatest public health issues world-
wide. Among gastrointestinal cancers, stomach or gastric cancer and colorectal
cancers remain the most common and lethal cancers globally. Emerging data
suggest that in addition to the proliferating cancer cells, the tumor microenviron-
ment plays an important role in deciding the fate of these cancers. Compelling
evidence further suggests that among the components of the tumor microenvi-
ronment, the neuromodulators are important non-cellular factors that influence
the progression of gastric and colorectal cancers by regulating key steps of
tumorigenesis like cell proliferation, migration, invasion, and the formation of
new blood vessels or angiogenesis. A better understanding of the underlying
mechanisms by which the neurotransmitters and neuropeptides function in
tumorigenesis is therefore essential for the development of new and novel
antitumor therapies. In this book chapter, we will discuss the important findings
from studi es investigating the roles of different neuromodulators in the growth
and progression of gastric and colorectal cancers. We will summarize the roles of
these important neurotransmitters and ne uropeptides, their receptors and target
cells and provide insights regarding the approaches that need to be taken in order
to better understand the connections between the neuromodulators, the tumor
microenvironment, and development and progression of gastric and colorectal
tumors, which might contribute to the unraveling of new therapeutic targets for
these cancers.
D. Chakroborty (✉) · C. Sarkar (✉) Department of Pathology, College of Medicine, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA e-mail: dchakroborty@southalabama.edu; csarkar@southalabama.edu
#
The Author(s), under exclusive license to Springer Nature Switzerland AG 2022 Interdisciplinary Cancer Research, https://doi.org/10.1007/16833_2022_93 Published online: 27 December 2022
151
152 D. Chakroborty and C. Sarkar
https://t.me/med1917
Keywords
Colorectal cancer · Gastric cancer · Neuropeptides · Neurotransmitters · Tumor microenvironment
1 Introduction
Gastrointestinal (GI) cancers which mainly include the malignancies derived from esophageal, stomach, and colorectum, are the most prevalent malignancies and significant healthcare burdens worldwide (Arnold et al. 2020; Huang et al. 2021; Wong et al. 2021; Guren 2019). Even with recent advances in diagnosis and therapy, GI cancers, particularly stomach/gastric (GC) and colorectal canc ers (CRC), remain most common and lethal cancers globally. According to GLOBOCAN 2020 data­base, CRC is the third most commonly diagnosed cancer in males and the second most common cancer in females. It is also the second leading cause of cancer-related deaths in both sexes. It accounts for 10% of all new cancer cases and 9.4% of cancer deaths worldwide. It is closely followed by GC, which ranks fifth in incidence with
5.6% of all new cancer cases and fourth in cancer-related mortalities (Sung et al.
2021). Even with all the research advancements, the pathogenesis of GI cancers
remains elusive, thereby limiting therapeutic options for these diseases (Joshi and Badgwell 2021; Siebenhüner et al. 2021; Di et al. 2019; Smith et al. 2021; Shang and Pena 2005).
It has been acknowledged now that the fate of solid tumors is decided not only by the proliferating cancer cells but also by the physiological state of the environment surrounding the tumor cells, i.e., the tumor microenvironm ent (TME) (Giraldo et al.
2019; Pedrosa et al. 2019; Son et al. 2020; Zeng et al. 2019; Romero-López et al. 2017; Kalluri 2016), which is comprised of apparently normal cells and components
that are hijacked by cancer cells to work in their favor and promote tumor growth and dissemination of cancer cells to the other parts of the body. The TME thus harbors tumor cells that interact with surrounding cells, which typically comprises of cellular components like immune cells, stromal cells, adipose cells, endothelial cells, neurons, and non-cellular components like cytokines, chemokines, growth factors, neuromodulators, and extracellular matrix (ECM) (Giraldo et al. 2019; Kalluri 2016; Thorsson et al. 2018; Anderson and Simon 2020; Quail and Joyce 2013; Laplane et al. 2018). These components of the TME interact with each other and with the cancer cells to create an environment conducive to the survival of the cancer cells (Giraldo et al. 2019; Kalluri 2016; Laplane et al. 2018). Furthermore, the cells in the TME also facilitate the escape of cancer cells from host immune surveillance and help them become more resistant to therapies (Giraldo et al. 2019; Pe drosa et al.
2019; Khalaf et al. 2021; Darragh et al. 2018; Datta et al. 2019). Over the past
decades, the contribution of the TME toward disease progression and therapeutic outcomes has become increasingly evident (Khalaf et al. 2021; Darragh et al. 2018; Datta et al. 2019; Smyth et al. 2016). There is a continued interest therefore in understanding the interactions between the cancer cells and the cells in the tumor
Role of Neuromodulators in Regulation of the Tumor Microenvironment.. . 153
https://t.me/med1917
milieu. Among the components of the TME, the neuromodulators are rapidly emerging as important non-cellular factors that in fluence the progression of cancers (Spindel 2012; Basu and Dasgupta 2000; Li and Cho 2011; Krüttgen et al. 2006; Kitlinska et al. 2006; Sejda et al. 2020; Zhang et al. 2019; Wei et al. 2021). Growing evidence suggests that neurotransmitters and neuropeptides regulate several steps of tumorigenesis like proliferation, migration, and invasion by tumor cells, and the formation of new blood vessels from existing vessels or angiogenesis to sustain the tumor cells (Basu et al. 2004; Chakroborty et al. 2008, 2009, 2011; Gomez-Flores et al. 2021; Hondermarck, and Jobling 2018; Krüttgen et al. 2006; Lin et al. 2021; Rubí and Maechler 2010; Sarkar et al. 2013; Sejda et al. 2020; Wei et al. 2021; Zahalka et al. 2017). A better understanding of the interactions of the neurotransmitters with cancer cells and other cells of the TME might therefore facilitate the development of new approaches for detection and therapy that can be used as novel strategies to complement the existing treatment options. Here, we focus on the recent advances in the understanding of the role of neuromodulators in the TME of GC and CRC.
2 Sources of the Neurotransmitters in GI Tract
The GI tract organs including colon and stomach are highly innervated as the GI tract not only has the nerve supply that is well connected to the brain and spinal cord, i.e., the central nervous system (CNS), but is also supplied by a dedicated nervous system, the enteric nervous system (ENS) embedded in the wall of the GI tract (Costa 2000; Lomax et al. 2009; Bharucha 2003; Phillips and Powley 2007; Uesaka et al. 2016; Burns and Thapar 2006). Together with CNS and sympathetic and parasympathetic branches of the autonomic nervous system, the ENS plays an important role in the maintenance of GI function and homeostasis (Costa 2000; Lomax et al. 2009; Kulkarni et al. 2018). Increased number of evidence in recent years suggests a strong multifaceted connection between GI homeostasis with the ENS/CNS function, disruption of which has been shown to be an underlying cause of number of GI diseases including cancers. Emerging reports have highlighted the critical role of the “brain-gut-axis”, which is the bidirectional communication between the CNS and the ENS, in tumorigenesis and development of GI cancers (Di et al. 2019; Kulkarni et al. 2018 ; Duraker et al. 2003; Schledwitz et al. 2021 ).
The ENS, also called the “brain of the gut”, is the largest component of the autonomic nervous system (Di et al. 2019; Burns and Thapar 2006; Kulkarni et al.
2018; Rao and Gershon 2018). It is composed of mesh-like arrangements of neurons
and glia structured in ganglia in the gut wall. The ENS in humans consists of over 300 million neurons, distributed in many thousands of small ganglia, constituting two major plexuses, the myenteric plexus and the submucosal plexus (Costa 2000; Rao and Gershon 2018; Hao and Young 2009; Fleming et al. 2020). The myenteric plexus (Auerbach plexus) lies between the longitudinal and internal circular layers of muscularis externa in the GI tract. It forms a continuous network from the upper esophagus to the internal anal sphincter (Costa 2000; Rao and Gershon 2018; Hao
154 D. Chakroborty and C. Sarkar
https://t.me/med1917
and Young 2009; Fleming et al. 2020). The submucosal plexus exists between the circular muscle layer and the mucosa and comprises at least 2 networks, Meissner plexus (closer to the mucosa) and Schabadasch plexus (adjacent to the circular muscle) (Hansen 2003). Submucosal ganglia and connecting fiber bundles form plexuses in the small and large intestines (Furness et al. 2014).
Enteric neurons synthesize and release a wide range of peptide and nonpeptide neurotransmitters (Rademakers et al. 2017). The chemical mediators found in the ENS include acetylcholine, dopamine (DA), epinephrine, norepinephrine, serotonin and nitric oxide, purines such as ATP, amino acids such as γ-aminobutyric acid, and peptides such as vasoactive intestinal polypeptide, substance P, and neuropeptide Y (Goyal and Hirano 1996; Mittal et al. 2017; McConalogue and Furness 1994). Overall, more than 20 candidate neurotransmitters have now been identified in enteric neurons.
3 Role of Important Neuromodulators in Modulating
the TME of Gastric and Colorectal Cancers
3.1 Acetylcholine
Acetylcholine (ACh) is a predominant neurotransmitter of the ENS (Kulkarni et al.
2018; Delvalle et al. 2018; Harrington et al. 2010; Yoo and Mazmanian 2017). The
gut wall is richly innervated with cholinergic neurons that synthesize and store ACh. In addition to ENS, non-neuronal sources like epithelial cells of colonic and gastric origins have been identified as potential sources of ACh in the GI tract (Yajima et al. 2011; Feldberg and Lin 1950). It is synthesized by a single-step reaction catalyzed by choline acetyltransferase (ChAT) via the enzymatic conversion of acetyl-CoA and choline to ACh and CoA. ACh is known to have both excitatory and inhibitory effects on the neuronal system. It mediates its functions by acting through nicotinic receptors (nAChRs) and muscarinic ACh receptor (mAChRs) expressed on the surface of cells (Kulkarni et al. 2018). mAChRs are G-protein­coupled receptors (GPCR) that express on the surface of smooth muscle cells. They have been reported to be overexpressed in GC and CRC (Kulkarni et al. 2018; Yang et al. 2016). Five mAChRs (M these five mAChRs, the distribution of M nant in the GI tract. M
AChRs co-express with smaller populations of M3AChRs.
2
Studies mostly show that ACh by acting through M metastasis of number of tumor cells (Xie et al. 2005; Yang et al. 2016; Wang et al.
2016). M
AChRs are most abundantly expressed in parietal cells and chief cells of
3
the stomach and are the major AChRs mediating gastric carcinogenesis. M overexpression in GC is correlated with disease stage and lymph node metastasis (Wang et al. 2016). It was reported that the stimulation of M increases the proliferation of these cells and knocking down of the receptor causes cell cycle arrest (G2/M) and promotes apoptosis (Wang et al. 2016). M the second most common AChRs and are known to express both in the parietal cells
) have been identified and characterized. Among
1-M5
AChRs has been shown to be predomi-
2
AChR promotes the growth and
3
AChR in GC cells
3
1
AChR
3
AChRs are